CONTEXT: Erythrocytosis is a dose-limiting adverse effect of testosterone therapy, especially in older men. OBJECTIVE: Our objective was to compare the dose-related changes in hemoglobin and hematocrit in young and older men and determine whether age-related differences in erythropoietic response to testosterone can be explained by changes in erythropoietin and soluble transferrin receptor (sTfR) levels. DESIGN: We conducted a secondary analysis of data from a testosterone dose-response study in young and older men who receivedlong-acting GnRH agonist monthly plus one of five weekly doses of testosterone enanthate (25, 50, 125, 300, or 600 mg im) for 20 wk. SETTING: The study took place at a General Clinical Research Center. PARTICIPANTS: Participants included 60 older men aged 60-75 yr and 61 young men aged 19-35 yr. OUTCOME MEASURES: Outcome measures included hematocrit and hemoglobin and serum erythropoietin and sTfR levels. RESULTS:Hemoglobin and hematocrit increased significantly in a linear, dose-dependent fashion in both young and older men in response to graded doses of testosterone (P<0.0001). The increases in hemoglobin and hematocrit were significantly greater in older than young men. There was no significant difference in percent change from baseline in erythropoietin or sTfR levels across groups in either young or older men. Changes in erythropoietin or sTfR levels were not significantly correlated with changes in total or free testosterone levels. CONCLUSIONS:Testosterone has a dose-dependent stimulatory effect on erythropoiesis in men that is more pronounced in older men. The testosterone-induced rise in hemoglobin and hematocrit and age-related differences in response to testosterone therapy may be mediated by factors other than erythropoietin and sTfR.
RCT Entities:
CONTEXT: Erythrocytosis is a dose-limiting adverse effect of testosterone therapy, especially in older men. OBJECTIVE: Our objective was to compare the dose-related changes in hemoglobin and hematocrit in young and older men and determine whether age-related differences in erythropoietic response to testosterone can be explained by changes in erythropoietin and soluble transferrin receptor (sTfR) levels. DESIGN: We conducted a secondary analysis of data from a testosterone dose-response study in young and older men who received long-acting GnRH agonist monthly plus one of five weekly doses of testosterone enanthate (25, 50, 125, 300, or 600 mg im) for 20 wk. SETTING: The study took place at a General Clinical Research Center. PARTICIPANTS: Participants included 60 older men aged 60-75 yr and 61 young men aged 19-35 yr. OUTCOME MEASURES: Outcome measures included hematocrit and hemoglobin and serum erythropoietin and sTfR levels. RESULTS: Hemoglobin and hematocrit increased significantly in a linear, dose-dependent fashion in both young and older men in response to graded doses of testosterone (P<0.0001). The increases in hemoglobin and hematocrit were significantly greater in older than young men. There was no significant difference in percent change from baseline in erythropoietin or sTfR levels across groups in either young or older men. Changes in erythropoietin or sTfR levels were not significantly correlated with changes in total or free testosterone levels. CONCLUSIONS:Testosterone has a dose-dependent stimulatory effect on erythropoiesis in men that is more pronounced in older men. The testosterone-induced rise in hemoglobin and hematocrit and age-related differences in response to testosterone therapy may be mediated by factors other than erythropoietin and sTfR.
Authors: S Bhasin; L Woodhouse; R Casaburi; A B Singh; D Bhasin; N Berman; X Chen; K E Yarasheski; L Magliano; C Dzekov; J Dzekov; R Bross; J Phillips; I Sinha-Hikim; R Shen; T W Storer Journal: Am J Physiol Endocrinol Metab Date: 2001-12 Impact factor: 4.310
Authors: Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen Journal: Endocr Rev Date: 2012-03-20 Impact factor: 19.871
Authors: E Del Fabbro; J M Garcia; R Dev; D Hui; J Williams; D Engineer; J L Palmer; L Schover; E Bruera Journal: Support Care Cancer Date: 2013-05-08 Impact factor: 3.603
Authors: Thomas W Storer; Shalender Bhasin; Thomas G Travison; Karol Pencina; Renee Miciek; Jennifer McKinnon; Shehzad Basaria Journal: J Clin Endocrinol Metab Date: 2016-04-06 Impact factor: 5.958
Authors: Stephen E Borst; Joshua F Yarrow; Christine F Conover; Unyime Nseyo; John R Meuleman; Judyta A Lipinska; Randy W Braith; Darren T Beck; Jeffrey S Martin; Matthew Morrow; Shirley Roessner; Luke A Beggs; Sean C McCoy; Darryl F Cannady; Jonathan J Shuster Journal: Am J Physiol Endocrinol Metab Date: 2013-12-10 Impact factor: 4.310